EB 1002
Alternative Names: EB-1002Latest Information Update: 01 Sep 2021
At a glance
- Originator Eden Biologics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Bone disorders
Highest Development Phases
- Preclinical Bone disorders
Most Recent Events
- 26 Aug 2021 EB 1002 is available for licensing in World as of 26 Aug 2021. https://www.edenbiologics.com/pipeline-3/
- 26 Aug 2021 Preclinical trials in Bone disorders (Prevention) in Taiwan (unspecified route) (Eden Biologics pipeline, August 2021)
- 19 Feb 2021 JHL Biotech is now called Eden Biologics